生长分化因子-15在心力衰竭风险或心衰但首次住院前患者中的预后价值
本研究为前瞻性纵向队列,纳入2166例A-C期心衰患者,测量GDF-15并分析其决定因素与预后价值。主要决定因素为年龄、糖尿病和NT-proBNP,但仅约一半变异可解释(R² 0.51)。对数转化GDF-15是结局最强预测因子(HR 2.12,95%CI 1.71-2.63),可提高风险预测准确性(连续NRI 0.26,95%CI 0.13-0.39)和临床净获益。
要点
- GDF-15是心衰风险或心衰但首次住院前患者结局的最强预测因子。
- GDF-15可增加预测模型的区分度和临床净获益,改善风险分层。
- 年龄、糖尿病和NT-proBNP是GDF-15的主要决定因素。
核心结论
- 在心力衰竭风险或心衰但首次住院前患者中,GDF-15提供独特信息,对心衰住院或全因死亡有高度预测价值,可改善风险分层和临床决策。
研究设计与样本
- 前瞻性纵向队列研究,连续纳入2166例A-C期心力衰竭患者,接受心血管磁共振和GDF-15测量。
- 中位随访1093天(939-1231天)。
- 主要结局为首次心衰住院或全因死亡的复合终点。
主要发现
- GDF-15的主要决定因素为年龄、糖尿病和NT-proBNP,但仅约一半变异可解释(R² 0.51)。
- 对数转化GDF-15是结局最强预测因子(HR 2.12,95%CI 1.71-2.63)。
- GDF-15加入模型后连续NRI为0.26(95%CI 0.13-0.39),并在整个阈值概率范围内提供更大临床净获益。
临床怎么用
- 对于心衰风险或心衰但首次住院前患者,可检测GDF-15以增强风险分层。
- GDF-15联合常规临床变量和NT-proBNP可能改善临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Identification of patients at risk of adverse outcome from heart failure (HF) at an early stage is a priority. Growth differentiation factor (GDF)-15 has emerged as a potentially useful biomarker. This study sought to identify determinants of circulating GDF-15 and evaluate its prognostic value, in patients at risk of HF or with HF but before first hospitalisation. METHODS: Prospective, longitudinal cohort study of 2166 consecutive patients in stage A-C HF undergoing cardiovascular magnetic resonance and measurement of GDF-15. Multivariable linear regression investigated determinants of GDF-15. Cox proportional hazards modelling, Net Reclassification Improvement and decision curve analysis examined its incremental prognostic value. Primary outcome was a composite of first hospitalisation for HF or all-cause mortality. Median follow-up was 1093 (939-1231) days. RESULTS: Major determinants of GDF-15 were age, diabetes and N-terminal pro-B-type natriuretic peptide, although despite extensive phenotyping, only around half of the variability of GDF-15 could be explained (R2 0.51). Log-transformed GDF-15 was the strongest predictor of outcome (HR 2.12, 95% CI 1.71 to 2.63) and resulted in a risk prediction model with higher predictive accuracy (continuous Net Reclassification Improvement 0.26; 95% CI 0.13 to 0.39) and with greater clinical net benefit across the entire range of threshold probabilities. CONCLUSION: In patients at risk of HF, or with HF but before first hospitalisation, GDF-15 provides unique information and is highly predictive of hospitalisation for HF or all-cause mortality, leading to more accurate risk stratification that can improve clinical decision making. TRIAL REGISTRATION NUMBER: NCT02326324.
引用
- Bradley, Schelbert, Bonnett, et al. Growth differentiation factor-15 in patients with or at risk of heart failure but before first hospitalisation. Heart. 2024. PMID: 37567614. doi:10.1136/heartjnl-2023-322857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。